SARS Mosaic S(N)
Description
Product Specs
The SARS Mosaic protein is shipped at room temperature. Upon receipt, it should be stored at -20 degrees Celsius.
Product Science Overview
The SARS-Associated Coronavirus Spike Mosaic S (N) Recombinant is a significant development in the field of virology and immunology. This recombinant protein is designed to enhance the immunogenicity and protective capacity of vaccines against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The spike (S) protein of SARS-CoV-2 plays a crucial role in the virus’s ability to infect host cells, making it a primary target for vaccine development.
The spike (S) protein of SARS-CoV-2 is a glycosylated transmembrane protein that forms the distinctive spikes on the surface of the virus. It is synthesized as a large precursor protein and must be activated by proteolytic cleavage into two subunits: S1 and S2 . The S1 subunit contains the receptor-binding domain (RBD) that binds to the host cell receptor, angiotensin-converting enzyme 2 (ACE2), while the S2 subunit facilitates membrane fusion, allowing the virus to enter the host cell .
The recombinant spike protein, specifically the Mosaic S (N) Recombinant, is engineered to include mutations that stabilize the protein and enhance its immunogenicity. One such modification involves the inactivation of the S1/S2 cleavage site and the introduction of mutations K986P and V987P, which help maintain the protein in a prefusion conformation . This stabilized version of the spike protein is expressed using a modified vaccinia virus Ankara (MVA) vector, which has shown promising results in preclinical studies .
Studies have demonstrated that the recombinant spike protein induces robust immune responses. Mice vaccinated with the stabilized spike protein mounted substantial levels of broadly reactive anti-S antibodies that effectively neutralized different SARS-CoV-2 variants . Additionally, intramuscular immunization of hamsters and mice with the recombinant spike protein resulted in potent immune responses upon challenge infection and provided protection from disease and severe lung pathology .
The development of the SARS-Associated Coronavirus Spike Mosaic S (N) Recombinant has broader implications for vaccine design and pandemic preparedness. By targeting conserved regions of the spike protein, such as the S2 subunit, researchers aim to develop vaccines that provide broad protection against multiple coronavirus variants and related zoonotic viruses . This approach could be crucial in addressing the ongoing challenges posed by viral evolution and immune escape.
